BioNTech stock has rebounded over the past year, yet the share price still screens as expensive on broad valuation checks after a steep 65.0% decline over five years. Recent lung cancer trial progress has put the spotlight back on the company, while the current pricing leaves investors weighing opportunity against what they are being asked to pay.

• Over the past 5 years, BioNTech has delivered a total return that declined 65.0%, which puts the recent recovery in a much longer period of weak performance.
• Upcoming presentations of lung cancer data, including new combinations and updated survival results, can support expectations for future revenue, while clinical and regulatory uncertainty around those same programs may limit how much valuation support investors are willing to give today.
• The broader checks point to a stock that leans expensive rather than a clear bargain, with a low value score of 2 out of 6.

The stock's next move may depend on whether BioNTech can deliver enough clarity on its lung cancer pipeline to justify paying what currently looks like a premium valuation.

Balance the recent rebound in BioNTech with other ideas by scanning hand picked quality stocks that still screen as inexpensive on our 49 high quality undervalued stocks.

Has BioNTech Run Too Far on Sales?

P/S is a useful check for BioNTech because the company is still heavily defined by current and expected revenue rather than steady profits. On this measure, BioNTech trades on a P/S of 9.3x, which is below the broader biotech industry average of 13.4x and also below the 10.8x peer group average. That leaves the stock priced at a discount to many revenue focused biotech stocks on simple comparisons.

The tailored fair value model, which adjusts for BioNTech’s margins, size and risk profile, points to a fair P/S ratio of 6.2x. That is meaningfully lower than the current 9.3x, so the shares still screen as overvalued even though they sit below industry and peer averages. Despite the recent attention on BioNTech’s lung cancer data, the current P/S already asks investors to pay a premium to what the model suggests is justified by the company’s fundamentals.

Overall, BioNTech stock appears overvalued on the P/S multiple even though it trades below the wider biotech group on this metric.

The BioNTech Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the BioNTech valuation puzzle leaves off and spell out what would need to happen for the stock to be worth significantly more or less than today's price. Each one ties its number to a specific view of how BioNTech's growth, margins and risks could evolve. This gives you something concrete to revisit as new trial data, guidance or regulatory decisions arrive on the Community page.

Community views on BioNTech are far apart, with some investors focused on the oncology opportunity and others on vaccine and trial risks.

Bull case: 5% undervalued

"Robust pipeline expansion in oncology, with multiple late-stage (Phase II/III) clinical trials for BNT327 and mRNA cancer immunotherapies across high-prevalence cancers (lung and breast), positions BioNTech to launch multiple new products, driving significant top-line revenue growth and enhancing earnings visibility over the next several years…"

Bear case: 36% overvalued

"Falling COVID-19 vaccine demand in core markets, including ongoing declines in U.S. vaccination rates and increased vaccine hesitancy globally, is expected to materially reduce long-term revenue from BioNTech's main commercial franchise as public adoption rates stagnate or deteriorate further…"

Do you think there's more to the story for BioNTech? Head over to our Community to see what others are saying!

The Bottom Line

BioNTech stock screens as overvalued on current market multiples, even after accounting for how it compares to peers. That does not rule out further upside, but it means you are already paying up for the lung cancer pipeline and broader oncology ambitions. The key question is whether upcoming clinical data and regulatory progress can support that premium and ease concerns around revenue concentration. Your view on how confidently BioNTech can turn its pipeline into durable, diversified sales is likely to drive whether the current valuation feels justified or stretched.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.